258 related articles for article (PubMed ID: 22308550)
1. Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis.
Sequeiros IM; Jarad N
Chron Respir Dis; 2012 Feb; 9(1):9-16. PubMed ID: 22308550
[TBL] [Abstract][Full Text] [Related]
2. Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations.
Sequeiros IM; Jarad NA
Chron Respir Dis; 2012; 9(4):213-20. PubMed ID: 22637747
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
4. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
Sawicki GS; Ayyagari R; Zhang J; Signorovitch JE; Fan L; Swallow E; Latremouille-Viau D; Wu EQ; Shi L
Pediatr Pulmonol; 2013 Oct; 48(10):954-61. PubMed ID: 23255309
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis.
Jarad NA; Giles K
Chron Respir Dis; 2008; 5(1):29-33. PubMed ID: 18303099
[TBL] [Abstract][Full Text] [Related]
6. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis.
Waters V; Atenafu EG; Salazar JG; Lu A; Yau Y; Matukas L; Tullis E; Ratjen F
J Cyst Fibros; 2012 Jan; 11(1):8-13. PubMed ID: 21849265
[TBL] [Abstract][Full Text] [Related]
7. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
[TBL] [Abstract][Full Text] [Related]
8. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis.
Amadori A; Antonelli A; Balteri I; Schreiber A; Bugiani M; De Rose V
Respir Med; 2009 Mar; 103(3):407-13. PubMed ID: 19027279
[TBL] [Abstract][Full Text] [Related]
9. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.
de Boer K; Vandemheen KL; Tullis E; Doucette S; Fergusson D; Freitag A; Paterson N; Jackson M; Lougheed MD; Kumar V; Aaron SD
Thorax; 2011 Aug; 66(8):680-5. PubMed ID: 21680566
[TBL] [Abstract][Full Text] [Related]
10. Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis.
Reece E; Segurado R; Jackson A; McClean S; Renwick J; Greally P
BMC Pulm Med; 2017 Apr; 17(1):70. PubMed ID: 28431569
[TBL] [Abstract][Full Text] [Related]
11. Effect of allergic bronchopulmonary aspergillosis on FEV
Kaditis AG; Miligkos M; Bossi A; Colombo C; Hatziagorou E; Kashirskaya N; de Monestrol I; Thomas M; Mei-Zahav M; Chrousos G; Zolin A
Arch Dis Child; 2017 Aug; 102(8):742-747. PubMed ID: 28325727
[TBL] [Abstract][Full Text] [Related]
12. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis.
Kraemer R; Deloséa N; Ballinari P; Gallati S; Crameri R
Am J Respir Crit Care Med; 2006 Dec; 174(11):1211-20. PubMed ID: 16959918
[TBL] [Abstract][Full Text] [Related]
13. Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.
Sanders DB; Zhao Q; Li Z; Farrell PM
Pediatr Pulmonol; 2017 Oct; 52(10):1268-1275. PubMed ID: 28881091
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations.
Sharma A; Kirkpatrick G; Chen V; Skolnik K; Hollander Z; Wilcox P; Quon BS
PLoS One; 2017; 12(2):e0171229. PubMed ID: 28178305
[TBL] [Abstract][Full Text] [Related]
15. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy.
Colombo C; Costantini D; Rocchi A; Cariani L; Garlaschi ML; Tirelli S; Calori G; Copreni E; Conese M
Pediatr Pulmonol; 2005 Jul; 40(1):15-21. PubMed ID: 15858808
[TBL] [Abstract][Full Text] [Related]
16. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
18. Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics.
Etherington C; Bosomworth M; Clifton I; Peckham DG; Conway SP
J Cyst Fibros; 2007 Jan; 6(1):67-73. PubMed ID: 16844430
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for lung disease progression in children with cystic fibrosis.
van Horck M; van de Kant K; Winkens B; Wesseling G; Gulmans V; Hendriks H; van der Grinten C; Jöbsis Q; Dompeling E
Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29773689
[TBL] [Abstract][Full Text] [Related]
20. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.
Waters V; Stanojevic S; Klingel M; Chiang J; Sonneveld N; Kukkar R; Tullis E; Ratjen F
J Cyst Fibros; 2015 Nov; 14(6):770-6. PubMed ID: 26265220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
